• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle.

作者信息

Hylek Elaine M

机构信息

Department of Internal Medicine, Boston University, Boston, Massachusetts, United States.

出版信息

Thromb Haemost. 2018 Dec;118(12):2018-2019. doi: 10.1055/s-0038-1676101. Epub 2018 Nov 19.

DOI:10.1055/s-0038-1676101
PMID:30453349
Abstract
摘要

相似文献

1
Treatment Persistence in Atrial Fibrillation: The Next Major Hurdle.心房颤动治疗的持久性：下一个主要障碍。
Thromb Haemost. 2018 Dec;118(12):2018-2019. doi: 10.1055/s-0038-1676101. Epub 2018 Nov 19.
2
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.在美国，新型口服抗凝剂用于治疗非瓣膜性心房颤动和静脉血栓栓塞患者时与华法林或安慰剂相比的医疗成本差异比较。
J Med Econ. 2015 Jun;18(6):399-409. doi: 10.3111/13696998.2015.1007210. Epub 2015 Feb 9.
3
Factors influencing dabigatran or warfarin medication persistence in patients with nonvalvular atrial fibrillation.影响非瓣膜性心房颤动患者达比加群或华法林药物治疗持续性的因素。
J Comp Eff Res. 2018 Jul;7(7):685-691. doi: 10.2217/cer-2017-0081. Epub 2018 May 29.
4
Health Care Resource Utilization, Costs, and Persistence in Patients Newly Diagnosed as Having Nonvalvular Atrial Fibrillation and Newly Treated With Dabigatran versus Warfarin in the United States.美国新诊断为非瓣膜性心房颤动且新接受达比加群与华法林治疗的患者的医疗资源利用、成本及持续性
Clin Ther. 2016 Mar;38(3):545-56.e1-6. doi: 10.1016/j.clinthera.2016.01.008. Epub 2016 Feb 5.
5
Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.新型口服抗凝药用于非瓣膜性心房颤动患者卒中预防的成本效益分析
Curr Cardiol Rep. 2015 Aug;17(8):61. doi: 10.1007/s11886-015-0618-4.
6
Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis.新型口服抗凝剂和华法林在房颤中的获益、风险和成本：一项多准则决策分析。
PLoS One. 2018 May 3;13(5):e0196361. doi: 10.1371/journal.pone.0196361. eCollection 2018.
7
Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.英国背景下新型口服抗凝剂预防心房颤动患者中风和全身性栓塞的成本效益比较。
Clin Ther. 2014 Dec 1;36(12):2015-2028.e2. doi: 10.1016/j.clinthera.2014.09.015. Epub 2014 Oct 23.
8
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.达比加群酯与维生素K拮抗剂预防心房颤动患者卒中的成本效益分析：法国医保支付方视角
Arch Cardiovasc Dis. 2014 Jun-Jul;107(6-7):381-90. doi: 10.1016/j.acvd.2014.04.009. Epub 2014 Jun 24.
9
Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.真实世界中开始接受口服抗凝治疗的非瓣膜性心房颤动患者的大出血风险及医疗保健经济结果。
J Med Econ. 2017 Sep;20(9):952-961. doi: 10.1080/13696998.2017.1341902. Epub 2017 Jun 22.
10
Novel oral anticoagulants vs warfarin for the management of postoperative atrial fibrillation: clinical outcomes and cost analysis.新型口服抗凝药与华法林用于术后房颤管理：临床结局与成本分析
Am J Surg. 2015 Dec;210(6):1095-102; discussion 1102-3. doi: 10.1016/j.amjsurg.2015.07.005. Epub 2015 Sep 18.

引用本文的文献

1
Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.优化心房颤动患者非维生素K拮抗剂口服抗凝治疗的依从性和持续性
Eur Heart J Suppl. 2022 Feb 14;24(Suppl A):A42-A55. doi: 10.1093/eurheartj/suab152. eCollection 2022 Feb.
2
Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study.直接口服抗凝剂与维生素K拮抗剂在非瓣膜性心房颤动中的疗效和安全性比较：一项加拿大多中心观察性队列研究。
CMAJ Open. 2020 Dec 18;8(4):E877-E886. doi: 10.9778/cmajo.20200055. Print 2020 Oct-Dec.
3
Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation.
探讨心房颤动患者口服抗凝药物持续性的方法学考虑。
Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):251-260. doi: 10.1093/ehjcvp/pvaa052.
4
Atrial Fibrillation in Older People: Concepts and Controversies.老年人的心房颤动：概念与争议
Front Med (Lausanne). 2019 Aug 8;6:175. doi: 10.3389/fmed.2019.00175. eCollection 2019.
5
Long-Term Persistence with Newly-Initiated Warfarin or Non-VKA Oral Anticoagulant (NOAC) in Patients with Non-Valvular Atrial Fibrillation: Insights from the Prospective China-AF Registry.非瓣膜性心房颤动患者中新发华法林或新型口服抗凝剂（NOAC）的长期持续应用：来自前瞻性中国房颤注册研究的观察。
Med Sci Monit. 2019 Apr 11;25:2649-2657. doi: 10.12659/MSM.915875.